Investigational tablet for peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an experimental oral drug (XNW5004) for people with peripheral T-cell lymphoma that has returned or not responded to previous treatments. It may stop lymphoma cells from growing, offering a new option when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have peripheral T-cell lymphoma that has come back or not improved after at least 2 previous treatments, including at least one newer drug.
- You have at least one tumor that can be measured on a scan or exam.
- You are willing to provide a tumor tissue sample (either from a past biopsy or a new one).
- You are generally in good health and able to care for yourself (ECOG score of 0 or 1).
- You have not had certain prior treatments (like EZH2 inhibitors, CAR-T therapy, or a stem cell transplant) within specific timeframes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral tablet called XNW5004 for people with peripheral T-cell lymphoma (a type of blood cancer) that has come back or not responded to prior treatments. The goal is to see if this drug can help shrink tumors or slow the disease.
This study tests two new drugs (SHR-0302 and SHR-2554) for people with a type of lymphoma (peripheral T-cell lymphoma) that has come back or not responded to prior treatment. The goal is to see if the combination can help control the cancer.
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
This study tests a new tablet called XNW5004 in patients with follicular lymphoma (a type of blood cancer) that has come back or stopped responding after multiple prior treatments. The goal is to see if this drug can help control the cancer in patients who have limited options.
This trial tests a new drug called XNW29016 for people with advanced cancer that has stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug, HH2853, for people with certain types of T-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
Hear when a new Relapsed/Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.